Summary The efficacy of high-dose intramuscular MPA therapy in controlling progressive measurable metastatic breast carcinoma was assessed in 32 women. In addition serial measurements of MPA blood levels were carried out in 20 of the patients and subjective effects of treatment were monitored in detail in 18 of the women. Overall 6 patients (19%) gained an objective response and a further 7 (22%) experienced disease stasis from 4-17 months whilst on treatment. Significant differences in serum MPA levels were seen between responders and non-responders, objective tumour shrinkage only being seen in those patients who rapidly attained, and sustained, blood levels in excess of 100ngml-1. Subjective assessment showed no evidence of a euphoriant effect of MPA therapy in the non-responders group.
Reports of high-dose Medroxyprogesterone acetate (MPA) administration in the treatment of advanced breast cancer began to appear in the mid 1970s and in 1979 a review of the published data concluded that an objective remission rate of 40% was seen in women who had not previously received cytotoxic therapy (Ganzina, 1979) . In addition to objective benefit the relative lack of toxicity of MPA combined with its ability to relieve pain (Pannuti et al., 1979) , improve performance status (Ganzia, 1979) , and increase appetite and body weight (Cavalli et al., 1983) led to the view that treatment carried a significant subjective benefit. Clinical trials showed that daily intramuscular doses of MPA of 500 mg or more were necessary for a significant incidence of response (Ganzina, 1979) , but pharmacokinetic studies have indicated considerable differences in bioavailability between patients (Salimtschik et al., 1980) . The present study set out across the objective response to high-dose MPA in women with advanced breast cancer and also to monitor both serum MPA levels and subjective effects of treatment in order to identify any correlations between these three parameters.
Materials and methods
The study was designed as an open, single group assessment and women with evaluable, progressing, locally recurrent or metastatic carcinoma of the breast which had failed to respond to, or relapsed after, conventional therapy were enrolled. Objectives response was assessed at monthly intervals and UICC criteria were adopted (Hayward et al., 1977 the questionnaire has been described elsewhere (Linssen et al., 1982; Stewart & van Dam, 1983 ) but it has not previously been used to prospectively monitor the subjective effects of a specific treatment. Questionnaires were completed before treatment, at weekly intervals during the induction phase and monthly thereafter for a total of three months.
Medroxyprogesterone acetate levels were measured in the serum samples by radioimmunoassay (Shrimanker et al., 1978) , blood being taken before treatment, weekly during induction and monthly thereafter. Following venepuncture the blood was allowed to clot and the serum separated and stored at -20°until analysed. The intra-assay variation was <10% and the inter-assay variation <15%. The specificity of the assay has been previously reported as >80% (Mathrubutham & Fotherby, 1981) and in the present series most samples were completely specific with -30% of the specimens showing small amounts (always <20%) of other material reacting with the antiserum.
Results
Thirty-two women entered the study, two died from rapidly progressive disease before completion of induction therapy, but have been included in the overall analysis. All patients had received extensive prior therapy (surgery in 24 cases, radiotherapy in 28, cytotoxic drugs in 23, tamoxifen in 31, other hormones in 15 and interferon in 3). The mean age of the group was 63 years (range 37-76) and all patients were post-menopausal.
Six patients (19%) had an objective response to treatment with 3 complete and 3 partial remissions. Details of the response rate for individual sites of disease are given in Table I . The mean duration of response was 12 months (range 8-16+), measured from the time of commencing MPA. One patient died at 14 months from other causes whilst still in Scores for subjective assessment over the first 3 months of treatment were available for 5 patients who showed an objective response and 13 with progressive disease. A preliminary analysis showed a tendency for the overall scores for the responders to increase during treatment whereas those of the non-responders declined (Priestman, 1984) . These global scores included a wide variety of factors and, in order to address the question of whether there was any euphoriant effect from the MPA therapy apparent in the non-responders, the nine parameters on the questionnaire specifically relating to the patient's feeling of well-being were analysed separately. (These were irritability, worry, depression, anxiety, tension and four questions on general mood and feelings).
The results are shown in Figure 2 and, although scores for responders rise initially (indicating improved wellbeing) whilst the non-responders scores remain essentially static, there is no statistical difference between the two groups at any point in time (Wilcoxon rank sum test). Twenty-two patients experienced side effects during treatment and in three these were of sufficient severity to stop treatment (Table III) . The elevation of haemoglobin was greater than 1 mg dl-I in 15 patients and in 7 of these it was >2mg dl'-but no symptoms resulted from this increase. The syndrome of trembling with or without muscle cramps and sweating usually only appeared after 2 to 3 months therapy and was mild in 6, moderate in 3 and severe in 3 cases. All but 
Discussion
Previous studies of high-dose MPA in advanced breast cancer have reported response rates ranging from 28% (Mattson, 1978) to 46% (Pannuti et al., 1979) in patients who had not previously received cytotoxic therapy and this figure has risen to over 70% when patients were selected according to oestrogen-receptor status (Mattson, 1980 Interpretation of the levels at and beyond this time is obscured by dose reductions, due to toxicity, and the fall off in the numbers of non-responders due to patients coming off treatment because of progressive disease. The shape of the curves for the two patient groups suggests that the responders may have been slower metabolisers of MPA, thus rapidly achieving high blood levels, and the possibility of there being different patterns of MPA metabolism which might be of therapeutic significance merits further investigation.
A universally accepted and completely validated system for monitoring subjective response has still to be defined and it would probably be premature to consider the results of any such analysis as conclusive. Given this caveat it was still considered important to try to identify whether MPA therapy was associated with a euphoriant effect. For this reason only these aspects of the EORTC questionnaire relating specifically to mood and well-being have been considered in the present analysis, excluding those parameters relating to physical status, symptoms of disease and sideeffects of therapy. On the basis of the data presented here no improvement in well-being could be identified in the non-responders and only a minimal transient benefit was recorded among those who showed objective regression of disease.
All the side effects seen in the present study have been reported previously. The significance of cardiovascular complications (myocardial infarction and increased frequency of anginal attacks) in two patients, and changes in thyroid function in two further women, remains to be determined with relation to MPA therapy. Compliance was not a problem and treatment was generally carried out on an outpatient basis, injections being given by the District Nurse. Although one patient did develop a severe gluteal abscess, this was only one case in a series involving over 1500 injections.
These results indicate that MPA has useful activity in either arresting disease progression or bringing about objective remission of worthwhile duration in women with end-stage breast carcinoma.
